Overview
On February 3, 2026, Barbara Weber - listed as a director and Executive Chair of Tango Therapeutics (NASDAQ: TNGX) - sold a combined 30,519 shares of the company's common stock in two separate trades. The transactions produced aggregate proceeds of approximately $374,293, with execution prices ranging from $11.88 to $12.91 per share.
Transaction detail
The bulk of the disposition consisted of 30,186 shares sold at a weighted average price of $12.2573. Individual sale prices within that block spanned $11.88 to $12.875 per share. The second, much smaller, transaction was for 333 shares at a weighted average price of $12.8971, with per-share prices between $12.88 and $12.91.
Related equity awards and holdings
The stock sales came one day after an equity award recorded on February 2, 2026. On that date Weber acquired 37,522 shares of common stock and 222,132 stock options. The equity awards are represented by restricted stock units (RSUs), each of which corresponds to a contingent right to receive one share of the issuer's common stock. According to the terms disclosed, the RSUs are slated to vest in full on February 1, 2027, contingent on the reporting person's continuous service with the issuer through the vesting date.
Following the February transactions, Weber is reported to directly own 1,629,254 shares of Tango Therapeutics common stock.
Corporate developments
Separately from the insider activity, Tango Therapeutics has established a $100 million at-the-market (ATM) offering under a sales agreement with Leerink Partners LLC. Under that agreement, Leerink Partners will serve as sales agent and may receive a commission of up to 3.0% of the gross sales price for any shares sold pursuant to the program. The agreement permits the company to supply common stock into the market at its discretion through the agent.
Equity research coverage remains supportive in the near term: Stifel has retained its Buy rating on Tango Therapeutics with a price target of $15.00. The firm cited recent updates on the company’s pipeline and strategic priorities for 2026, and pointed to vopimetostat as a potential best-in-class PRMT5 inhibitor as part of its positive assessment.
Leadership and governance changes
Tango has also adjusted its senior leadership and board composition. Malte Peters has been named the company’s new chief executive officer, succeeding founding CEO Barbara Weber. The company notes Weber will transition to the role of Executive Chair for 2026. In addition, Sung Lee has been appointed to the board of directors, bringing more than 20 years of finance leadership experience to the corporate governance team.
Contextual note
The information above reflects the reported insider transactions, equity awards and corporate actions as disclosed. Where vesting or other contingencies are specified, they apply only as described and are dependent on the conditions explicitly noted by the company.